After eight daunting months of battling COVID-19, there may be some light at the end of the tunnel as two potential vaccine candidates recently announced promising test results. 

Vaccines from Pfizer and Moderna are similar in that they both use emerging technology called messenger ribonucleic acid (mRNA) to reach nearly 95 percent efficacy. Typically, scientists create vaccines by using live or inactivated virus cells, which puts the actual disease into a person’s body. However, with mRNA technology, Pfizer and Moderna were able to avoid that. MRNA carries coded instructions that tell cells what defenses are necessary by appearing as a threat. 

Of Course, There's a Catch

The use of the molecule is groundbreaking for a number of reasons. One is the speed at which the vaccines were developed. The other is that the use of mRNA means the vaccines contain no infectious COVID-19 properties that could get patients sick. 

However, there is a drawback to the vaccines: they have to be stored in brutally cold temperatures.

Under normal circumstances, vaccines can survive when stored at around 40 degrees Fahrenheit, but for Moderna, the vials must be stored at -4 degrees.

For Pfizer's vaccine, the threshold for keeping an effective dose is even steeper at a staggering -94 degrees. The icy temperatures are necessary to keep the mRNA molecule intact, otherwise it “begins to fall apart and twist around in ways so that it doesn’t become effective,” a representative for the pharmaceutical giant told Cheddar.

Vaccine Storage & Distribution Roadblock

With the need for cold storage comes the obstacle of how to pull off widespread distribution. Most hospitals in the U.S. do not house facilities that meet the requirements to store either the Moderna or Pfizer vaccines for extended periods. Both vaccines are able to survive in typical storing temperatures of 35 to 46 degrees, but their shelf lives are limited that way.

For Pfizer, the vaccine would no longer be effective after five days in normal storage temperatures. Moderna, meanwhile, shows more promise when it comes to effective distribution as it’s vaccines appear to remain effective for a month while stored 35 degrees.

Pfizer has come up with a plan to ship its vaccine in boxes filled with dry ice. The vials will remain protected for up to 15 days -- but the container can only be opened up to two times per day. 

This could be a logistical nightmare for parts of the world that don't have sufficient equipment - or enough dry ice - to keep the vaccines. Even in rural America, many hospitals don't have freezers that can keep doses cold enough, particularly for the Pfizer vaccine.  

Getting Vaccinated

So what does this mean for you? Once the FDA approves emergency use authorization of either one or both of the vaccines, it looks like they will likely be distributed first among populations that need it the most: frontline healthcare workers, the elderly, and those suffering from underlying health conditions. 

Like several existing vaccinations for other conditions, both Pfizer and Moderna require two rounds of treatment in order for the body to build up complete immunity. For those receiving the Pfizer vaccine, patients will need to return for a second dose after three weeks and for those getting the Moderna vaccine, they'll have to go back for round two after four weeks. 

Video produced by Ali Larkin. Article written by Lawrence Banton.

Share:
More In Science
FDA Panel Recommends Pfizer Vaccine for Kids Ages 5-11
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
A Look Ahead at G20 Summit and COP26 on Addressing the Climate Crisis
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Expanding Genetic Testing for Women Everywhere
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Proptech Startup Juno Raises $20 Million
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Innovation in Breast Cancer Screening
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
Merck to Offer Poorer Countries COVID-19 Pill Formula for Free
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Deal or No Deal, ISIS Threat & Memecoin Insanity
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
Load More